行情

ARWR

ARWR

箭头制药
NASDAQ

实时行情|Nasdaq Last Sale

35.95
-0.65
-1.78%
盘后: 36.00 +0.05 +0.14% 19:02 10/18 EDT
开盘
36.89
昨收
36.60
最高
38.75
最低
35.60
成交量
364.48万
成交额
--
52周最高
38.75
52周最低
10.41
市值
34.26亿
市盈率(TTM)
78.63
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ARWR 新闻

  • Biotech Says It Hurdled A Genetic Barrier, But Shares Gave Up A Breakout
  • Investor's Business Daily.2天前
  • Arrowhead Pharmaceuticals Is Flying Higher on the Charts
  • TheStreet.com.2天前
  • Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics
  • Business Wire.2天前
  • The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe
  • Benzinga.2天前

更多

所属板块

生物技术和医学研究
-1.17%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

ARWR 简况

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
展开

Webull提供Arrowhead Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。